NetworkNewsBreaks – CytoDyn Inc. (CYDY) Interim CMO to Present at 11th Annual Conference on Stem Cell and Regenerative Medicine

CytoDyn Inc. (OTCQB: CYDY), a biotechnology company developing innovative treatments for multiple therapeutic indications, this morning announced that Richard G. Pestell, M.D., Ph.D., president of the Pennsylvania Cancer and Regenerative Medicine Research Center, distinguished professor at the Baruch S. Blumberg Institute and interim chief medical officer of CytoDyn, will deliver the keynote plenary speech at the 11th Annual Conference on Stem Cell and Regenerative Medicine in Helsinki, Finland. Pestell’s presentation, titled ‘Cancer stem cells, genetic drivers and therapeutic targeting via CCR5’, is scheduled to take place on Monday, October 15, from 10-11 am EEST. Pestell will present recent scientific evidence demonstrating the effectiveness of PRO 140 (leronlimab), which is shown to bind to CCR5 in human breast cancer, block CCR5 signaling induced by cytokines and block human breast cancer cell invasion.

To view the full press release, visit http://nnw.fm/SgzM0

About CytoDyn

CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on PRO 140 (leronlimab), a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a key role in the ability of HIV to enter and infect healthy T-cells.  The CCR5 receptor is also implicated in tumor metastasis and in immune-mediated illnesses such as graft-vs-host disease (GvHD) and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with PRO 140 in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. The Company plans to seek FDA approval for PRO 140 in combination therapy and plans to complete the filing of a Biological License Application (BLA) in the first quarter of 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with PRO 140 as a once-weekly monotherapy for HIV-infected patients, and plans to initiate a registration-directed study of PRO 140 monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that PRO 140 monotherapy can prevent viral escape in HIV-infected patients, with some patients on PRO 140 monotherapy remaining virally suppressed for more than four years. CytoDyn is also conducting a Phase 2 trial to evaluate PRO 140 for the prevention of GvHD and expects to initiate clinical trials with PRO 140 in metastatic triple-negative breast cancer in 2018. For more information, visit the company’s website at www.CytoDyn.com

More from NetworkNewsBreaks

NetworkNewsBreaks – FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) Investee Adds Taxation Reporting Technology to its Proprietary Compliance Platform NetworkNewsBreaks – First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) Announces Results of Independent Studies Supporting Restart of Canadian Refinery NetworkNewsBreaks – The Flowr Corporation (TSX.V: FLWR) Ships Initial Purchase Order from the NSLC

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire has received compensation from CytoDyn Inc. for providing certain investor relations, marketing and social media services, including the preparation of this report, and expects to receive additional compensation for such services in the future. This compensation includes a monthly program fee.

Latest News

AP-NORC Poll: Disasters influence thinking on climate change

Jan 22, 2019

WASHINGTON — When it comes to their views on climate change, Americans are looking at natural disasters and their local weather, according to a new poll. Lately, that means record deadly wildfires in California, rainfall by the foot in Houston when Hurricane Harvey hit and the dome of smog over Salt Lake City that engineer Caleb Gregg steps into when he walks out his door in winter. "I look at it every day," Gregg said from Salt Lake City, where winter days with some of the country's worst air starting a few years ago dinged the city's reputation as a...

Armed with affection, octogenarian is an 'octopus whisperer'

Jan 22, 2019

BOSTON — Wilson Menashi palmed a squid in his left hand and extended his arm into an aquarium tank, watching as a giant Pacific octopus stretched out arms to greet him like a friend. Freya latched some of her 2,240 suction cups onto Menashi's arm, using their powers of taste and smell to gather information around the 84-year-old man known as the octopus whisperer — and the seafood treats he was bearing. "She's just contacting me and she's saying, 'You come to me,'" Menashi said of Freya, a 3-year-old predator weighing 35 to 40 pounds (18 kilograms). Her arms span...

Toyota, Panasonic announce venture for green auto batteries

Jan 22, 2019

TOKYO — Toyota Motor Corp. and Panasonic Corp. are setting up a joint venture to research, manufacture and sell batteries for ecological autos, an increasingly lucrative sector amid concerns about global warming. The Japanese automaker and the Japanese electronics maker said in a joint statement Tuesday that Toyota will take a 51 percent stake and Panasonic 49 percent in the joint venture, which is to be running by the end of 2020. The companies have been studying working together on batteries since 2017. They did not say how much would be invested in the joint venture. Panasonic will transfer equipment,...

China seems to confirm scientist's gene-edited babies claim

Jan 22, 2019

Chinese authorities appear to have confirmed a scientist's unpublished claim that he helped make the world's first gene-edited babies and that a second pregnancy is underway, and say he could face consequences for his work. China's official Xinhua News Agency said Monday that investigators in Guangdong province determined that the scientist, He Jiankui (HUH JEEN-qway), evaded supervision of his work and violated research norms because he wanted to be famous. The report said He acted alone and will be punished for any violations of the law, although it didn't say which regulations he may have broken. The scientist stunned the...

2-for-1: Total lunar eclipse comes with supermoon bonus

Jan 22, 2019

CAPE CANAVERAL, Fla. — The only total lunar eclipse this year and next came with a supermoon bonus. On Sunday night, the moon, Earth and sun lined up to create the eclipse, which was visible throughout North and South America, where skies were clear. There won't be another until the year 2021. It was also the year's first supermoon, when a full moon appears a little bigger and brighter thanks to its slightly closer position. The entire eclipse took more than three hours. Totality — when the moon's completely bathed in Earth's shadow — lasted an hour. During a total...

Broaden News

About Us

In-Depth Science delivers comprehensive and compelling news and analysis on everything science and technology, seven days a week in a reader-friendly format.

Contact us: sales@indepthscience.com